Related Experiment Video
Updated: Jan 23, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile
Jie Xu1,2,3,4, Anxin Wang1,2,3,4, Runqi Wangqin5
1Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Insights
Dual antiplatelet therapy (DAT) with clopidogrel plus aspirin shows no overall benefit for minor stroke/transient ischemic attack patients with CYP2C19 loss-of-function alleles. However, high-risk patients with these alleles significantly benefit from DAT.
Area of Science:
- Neurology
- Pharmacogenomics
- Cardiovascular Medicine
Background:
- Dual antiplatelet therapy (DAT) with clopidogrel and aspirin is recommended for minor stroke (MS) and transient ischemic attack (TIA) patients.
- The efficacy of DAT may be influenced by genetic factors, specifically CYP2C19 genotype.
Purpose of the Study:
- To identify patient subgroups who benefit from DAT in MS/TIA.
- To compare the effectiveness of clopidogrel-aspirin versus aspirin alone in MS/TIA patients stratified by CYP2C19 genotype and risk profiles.
Main Methods:
- Patients with MS/TIA were stratified based on CYP2C19 loss-of-function allele (LoFA) status and Essen Stroke Risk Score (ESRS) into low (<3) and high (≥3) risk groups.
- Stroke recurrence at 1 year was the primary outcome, comparing clopidogrel-aspirin therapy against aspirin monotherapy.
Main Results:
- No significant difference in stroke recurrence was observed between DAT and aspirin alone for overall LoFA carriers (11.2% vs 13.3%).
- Significant benefits of DAT were found in specific subgroups: LoFA carriers at high risk (HR=0.63), LoFA noncarriers at low risk (HR=0.62), and LoFA noncarriers at high risk (HR=0.52).
- A significant interaction (p=0.021) was detected between CYP2C19 genotype and risk profile in determining DAT efficacy.
Conclusions:
- Overall, CYP2C19 LoFA carriers do not appear to benefit from DAT for MS/TIA.
- High-risk LoFA carriers represent a subgroup that significantly benefits from clopidogrel-aspirin therapy.
- The effectiveness of clopidogrel in Chinese MS/TIA patients is dependent on both CYP2C19 genotype and clinical risk profile.
Objective:
Dual antiplatelet therapy (DAT) with clopidogrel plus aspirin has been suggested by American Heart Association/American Stroke Association guidelines for minor stroke (MS) and transient ischemic attack (TIA) patients. The purpose of this study was to find the potential subgroups that benefit from DAT. We aimed to compare the efficacy of clopidogrel-aspirin therapy with that of aspirin therapy in MS/TIA patients stratified by CYP2C19 genotype and risk profiles.
Methods:
CYP2C19 loss-of-function allele (LoFA) carriers were defined as patients with LoFA of either *2 or *3. Low- and high-risk profile was defined as Essen Stroke Risk Score (ESRS) <3 and ≥3, respectively. Stroke recurrence at 1 year was considered primary outcome.
Results:
Of a total 2,933 MS/TIA patients, there were 1,726 (58.8%) LoFA carriers and 1,068 (36.4%) patients at high risk (ESRS ≥3). No significant difference for stroke recurrence between the clopidogrel-aspirin group and aspirin alone group was found in LoFA carriers (11.2% vs 13.3%, hazard ratio [HR] = 0.83, 95% confidence interval [CI] = 0.64~1.09). In stratified analyses by CYP2C19 genotype and ESRS, HRs (95% CIs) of the clopidogrel-aspirin therapy for stroke recurrence were 1.00 (0.70~1.42), 0.63 (0.41~0.97), 0.62 (0.40~0.96), and 0.52 (0.31~0.88) among subgroups of LoFA carriers at low risk, LoFA carriers at high risk, LoFA noncarriers at low risk, and LoFA noncarriers at high risk, respectively, with p = 0.021 for interaction.
Interpretation:
Overall, LoFA carriers do not benefit from DAT, but there is significant benefit for LoFA carriers who are at high risk. The benefit of clopidogrel in Chinese MS/TIA patients depends on CYP2C19 genotype and risk profile. ANN NEUROL 2019;86:419-426.
More Related Videos
Related Concept Videos
Self-Efficacy
Relative Risk
Frequency-dependent Selection
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Drug Dependence
Contact-dependent Signaling
Gap Junctions
In animal cells, gap junctions are formed...

